Valuation: argenx SE

Market Cap 50.31B 44.94B 41.89B 37.98B 71.47B 4,775B 72.03B 502B 196B 2,484B 189B 185B 7,969B P/E 2026 *
27.1x
P/E 2027 * 20.8x
Enterprise Value 46.6B 41.63B 38.8B 35.18B 66.21B 4,424B 66.73B 465B 182B 2,301B 175B 171B 7,383B EV / Sales 2026 *
7.4x
EV / Sales 2027 * 5.74x
Free-Float
99.99%
Yield 2026 *
0.05%
Yield 2027 * 0.1%
1 day-1.19%
1 week-13.74%
Current month-16.30%
1 month-18.46%
3 months-8.40%
6 months-0.82%
Current year-4.56%
1 week 787.73
Extreme 787.73
832.49
1 month 787.73
Extreme 787.73
1,003.83
Current year 661.85
Extreme 661.85
1,072.75
1 year 661.85
Extreme 661.85
1,072.75
3 years 327.72
Extreme 327.725
1,072.75
5 years 249.5
Extreme 249.5
1,072.75
10 years 17.33
Extreme 17.33
1,072.75
Manager TitleAgeSince
Chief Executive Officer 47 2026-05-05
Director of Finance/CFO 56 2021-05-31
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Chairman 54 2026-05-05
Director/Board Member 76 2015-05-12
Director/Board Member 65 2016-04-27
Change 5-day change 1-year change 3-year change Capi.($)
-1.19%-13.74% - - 50.31B
-0.32%-5.97%+57.78%+74.48% 70.44B
-1.99%-13.92%+3.01%+51.60% 50.31B
-1.32%-1.70%+6.99%+35.47% 47.51B
-0.58%+0.27%+27.93%+30.76% 42.91B
-2.84%-5.72%+286.54%+530.02% 40.39B
-0.38%-3.78%+6.74%+95.25% 39.69B
-0.39%-1.48%+10.41%+43.19% 30.59B
-0.78%-10.41%+46.57%+3.67% 26.8B
-7.13%-7.02%-12.99%-14.07% 22.36B
Average -1.70%-5.65%+48.11%+94.49% 41.22B
Weighted average by Cap. -1.41%-5.61%+50.86%+100.11%

Financials

2026 *2027 *
Net sales 6.3B 5.63B 5.25B 4.76B 8.95B 598B 9.02B 62.84B 24.6B 311B 23.66B 23.14B 998B 7.76B 6.93B 6.46B 5.86B 11.03B 737B 11.11B 77.41B 30.31B 383B 29.15B 28.51B 1,229B
Net income 1.13B 1.01B 942M 854M 1.61B 107B 1.62B 11.28B 4.42B 55.83B 4.25B 4.15B 179B 2.37B 2.12B 1.98B 1.79B 3.37B 225B 3.4B 23.67B 9.27B 117B 8.91B 8.72B 376B
Net Debt -3.7B -3.31B -3.08B -2.8B -5.26B -352B -5.3B -36.95B -14.46B -183B -13.91B -13.61B -587B -5.76B -5.14B -4.79B -4.35B -8.18B -547B -8.25B -57.44B -22.49B -284B -21.63B -21.15B -912B
Projected Income Statement - Annual - argenx SE
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
26-10-13 US$802.64 -1.19% 277,151
26-10-12 US$812.30 -1.54% 241,201
26-10-09 US$825.03 +0.78% 512,248
26-10-08 US$818.63 -11.83% 2,454,224
26-10-07 US$928.44 -0.22% 258,329
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - argenx SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
804.43USD
Average target price
1,139.39USD
Spread / Average Target
+41.64%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - argenx SE